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ABSTRACT
Toxic epidermal necrolysis (TEN) is a life-threatening dermatological disorder characterized by erythematous lesions, necrosis, exfoliation, sepsis, 
and death. This may be due to different reasons such as chemical exposure, systemic infections, or some reactions of drugs such as carbamazepine, 
phenytoin, allopurinol, lamotrigine, and nonsteroidal anti-inflammatory drugs. In this case, the patient was on carbamazepine for the management 
of alcohol withdrawal symptoms. Moreover, this might be the reason for the occurrence of TEN. For his condition, he had given corticosteroids, 
antibiotics for sepsis, and other supportive measures.
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INTRODUCTION
The skin is the external covering for humans and helps us interact with our 
surroundings. The skin is, however, prone to a number of ailments, either 
due to the substances they come in contact with or due to the substances 
we consume. Toxic epidermal necrolysis (TEN) such as Stevens-Johnson 
syndrome (SJS) is rare reactions to the drug that is seriously cutaneous 
and could even lead to death [1,2]. In up to 95% of its occurrences, 
drugs are usually the major cause [3,4]. Quinolones, penicillins, and 
macrolides such as erythromycin, chloramphenicol, and sulfonamides 
are antibacterial drugs that are associated with the skin condition. TEN is 
also believed to be triggered by anticonvulsants such as carbamazepine, a 
derivative of antiepileptic iminostilbene that is used for treating epilepsy. 
Carbamazepine aids the reduction of nerve impulses in the body that 
causes pain and seizures, thereby making it effective for treating epilepsy 
and pain-related ailments. It is also effective for the treatment of bipolar 
disorder and for the management of alcohol withdrawal symptoms. The 
most frequently observed adverse effects of carbamazepine include 
hematological disorders, vomiting, and nausea. Chronic therapy with 
antiepileptic drugs such as carbamazepine possesses a significant 
risk for developing osteoporosis and anemia [5]. There are rare cases, 
where it leads to reactions such as TEN and SJS, that is, life-threatening. 
Carbamazepine-induced systemic lupus erythematosus is another rare 
and serious adverse drug reaction that has been reported [6].
Some common indications of TEN include bullous detachment of the 
mucous membranes and epidermis, necrosis, and erythema, resulting in 
exfoliation and ultimately leading to sepsis or death. TEN is a condition 
that is normally unique to every individual, thereby, making it difficult to 
predict its occurrence. This has also made it difficult to properly explain 
the “TEN” pathophysiology. A number of theories have been widely 
accepted. Recent studies have revealed a strong association between 
HLA-B*1502 and CBZ-induced TEN/SJS [7]. TEN is believed to be an 
immune reaction that is cytotoxic, fighting keratinocytes that display 
antigens that are foreign to the body. It is similar to the hypersensitivity 
reaction, recognized by an antigen initial exposure reaction that is delayed, 
and a quick increasing reaction is noticed when the exposure is repeated.
The careful and prompt recognition of the problem and removal of all 
potential agents causing it is the best way to manage TEN. Supportive 
care pending the regeneration of the epithelium is the most effective 
treatment for TEN. The major supportive measure includes protective 
dressings, pain management, nutritional support, electrolyte, and fluid 
balance as well as isolation. Patients transfer to intensive or burn care 
unit early enough is a great way of considerably reducing the length of 
hospitalization, mortality rate, and infection rate. The agent leading to the 
reaction must be stopped instantly. Titrations and fluids administration, 
in line with urine output and central venous pressure, are vital. On 
an average, 3–4 L of fluid are required for those individuals who have 
50% of the surface area of their body affected. Pharmacotherapy in 
TEN is carried out with the aim of avoiding complications and reducing 
morbidity. While agents including antiseptics, analgesics, anticoagulants, 
antihistamines, antibiotics, and crystalloids agents are considered vital 
for supportive care, there is no specific modality for treatment. TEN 
management with corticosteroids is still controversial.
CASE REPORT
A male patient, aged 40 years, was brought to our hospital with 
complaints of bullous lesions followed by skin peeling and erosions. 
About 2 weeks back, the patient had been to a deaddiction center and 
was started on carbamazepine (single dose of 200 mg), baclofen, and 
thiamine 150 mg. Later, he had developed bullous lesions (initially 
started over lips, then eyelids, trunk, and limbs) and low-grade fever 
and was given intravenous (IV) steroids.
On admission, patients were conscious but had mild disorientation 
and vitals were stable. Physical examination revealed multiple 
erythematous and bullous lesions all over the body with erosions 
in the oral cavity and eyelids. Systemic examination was within the 
normal limits. Inflammatory markers were elevated (C-reactive 
protein -1773.33 nmol/L and erythrocyte sedimentation rate - 23 mm/h) 
with deranged liver function test with mildly raised total bilirubin 
(25.99 umol/L) and direct bilirubin (8.55 umol/L) and dyselectrolytemia 
(calcium - 1.9 mmol/L, phosphorous - 0.68 mmol/L, sodium - 124 mmol/L, 
and potassium - 3.4 mmol/L). Urine routine done was found to be normal.
The patient was initially admitted under dermatology department 
and he was started on injection hydrocortisone 100 mg, and IV fluid 
with a diagnosis of TEN due to carbamazepine. The patient was nursed 
in reverse isolation in view of extensive skin involvement and was 
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started empirically on tablet azithromycin 500 mg optometrist (OD). 
Ophthalmology consultation was sought for erosions over upper and 
lower eyelids and advised refresh liquigel, Genteal gel, and Milflox gel 
(ciprofloxacin 0.3% and dexamethasone 0.1%). Psychiatry consultation 
was sought for further treatment of alcohol withdrawal. Urine culture 
showed growth of Pseudomonas aeruginosa. Physical examination 
revealed that the patient was tachycardic, febrile and on view of his 
raised procalcitonin levels (19.85 ug/L), he was started on injection 
Piptaz (piperacillin/tazobactam) 3.375 g Q8H, injection teicoplanin 
400 mg Q24H, and injection thiamine 100 mg OD. He was continued on 
injection hydrocortisone 100 mg TID and all eye drops refresh liquigel 
Q6H, Genteal gel, and Milflox eye drops TID. Dyselectrolytemia was 
corrected and saline compresses were given over the lesions.
Once the patient becomes hemodynamically stable, he was started 
on tablet cyclosporine 100 mg OD. Skin lesions over the face and 
trunk started forming crusts and were gradually healing. Fusidic 
acid was added for local application over the erosions. Lesions 
started healing and reepithelization was seen. IV steroids (injection 
hydrocortisone) were tapered to twice daily and then once a day. 
Injection Piptaz and teicoplanin were continued for 14 days. The 
patient was hemodynamically stable at the time of discharge. Hence, 
injection hydrocortisone (100 mg) was changed to tablet Wysolone 
(prednisolone) 30 mg and he was advised to review in psychology 
outpatient department for counseling.
DISCUSSION
Our patient is a 40-year-old male with a history of chronic alcoholism. 
He was started on carbamazepine for the management of alcohol 
withdrawal symptoms. Moreover, this might have contributed to the 
occurrence of TEN. Naranjo adverse drug reaction probability scale was 
used to score and assess the causality of TEN in this context, and it was 
found to be 8 (probable). The patient recovered after stopping the drug. 
Challenge was not carried out due to the potential risk involved.
In our case, the patient was treated with injection hydrocortisone and 
when he was hemodynamically stable, it was switched to oral form. He 
was septic at the time of admission, but he improved on IV antibiotics 
without any complications or sequelae.
The use of IV corticosteroids in the management of TEN has limited 
trials and is still controversial. Hypothetically, corticosteroids increase 
the chance of sepsis and protein catabolism and decrease the rate 
of reepithelialization, their use is contraindicated in patients with 
extensive skin detachment.
However, in a retrospective study of 281 patients with SJS/TEN, only 
18% mortality rate was observed in the corticosteroid group, while 
in the IV immunoglobulin and supportive care group, it was 25%. The 
odds ratio of death for those patients who were on steroids compared 
to those on supportive cares alone was 0.6, demonstrating a potential 
benefit [8,9].
CONCLUSION
TEN is an uncommon but fatal skin disorder. Hence, early detection 
and diagnosis (through biopsy) are very important. The prompt 
identification and withdrawal of the offending drug are crucial. In 
our study, the culprit drug was carbamazepine, which was prescribed 
for the management of alcohol withdrawal symptoms. In such cases, 
Levetiracetam can be the drug of choice [10,11]. The United States Food 
and Drug Administration has recommended for prospective screening 
for specific genotypes contributing to its occurrence like HLA-B*1502 
allele, before the commencement of treatment with suspected 
drugs [7]. This could possibly decrease the burden of incidence of TEN. 
Future prospectives should be aimed at revamping the prevention and 
management of occurrence of such devastating form of adverse drug 
reactions.
Even though the use of IV steroids is controversial, it did not cause any 
significant variance in outcome in our case. Along with the medication 
therapy, supportive care is also an essential factor for the mitigation of 
this condition.
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